Iovance Biotherapeutics, Inc. (IOVA) saw its stock price plummet by 5.17% during Tuesday's trading session, following a mixed Q4 earnings report and an update on the Amtagvi launch.
Chardan Capital Markets, a research firm, lowered its price target for IOVA to $30 from $34, citing the company's Q4 results and Amtagvi launch update. However, Chardan maintained a Buy rating on the stock, indicating that they still see potential upside.
According to Chardan's analysis, while the Amtagvi launch hit its total revenue target, it relied heavily on contributions from Proleukin, another drug in IOVA's portfolio. The firm also noted that IOVA provided updates on its pipeline progress and upcoming catalysts during the Q4 report.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。